Massive discount to net cash, reputable management, and activist in place.
This is a clinical-stage biopharma whose only drug recently stumbled in a pivotal trial, sending the stock down over 80%. The collapse left the company trading at a massive discount to net cash, even after stripping out every liability on the balance sheet. Within days, a biopharma-focused activist disclosed a sizeable position bought right around current levels.
With the data in hand, the drug looks clearly uncompetitive against better-performing peers. The activist is in place (so far via a 13G), the stock is tightly held by biopharma funds, and management has a credible track record, including a prior wind-down-and-sell situation on the chairman’s resume. There is a clear path where the trial gets halted, the company launches a strategic review, and the stock re-rates materially higher. Final trial results could also still surprise on efficacy, which is an alternative path to win.
The margin of safety is wide enough to simply wait and see how things develop. And even if nothing happens, the downside from here should be limited.
This post is for paid subscribers, to continue reading please log in or sign up.